Investigational drug · Phase 3
AAV2-hRPE65v2
Also called: voretigene neparvovec-rzyl
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Leber Congenital Amaurosis, Inherited Retinal Dystrophy Due to RPE65 Mutations.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "AAV2-hRPE65v2"
First trial start
2010
Nov 2010
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AAV2-hRPE65v2", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leber Congenital Amaurosis
- Inherited Retinal Dystrophy Due to RPE65 Mutations
Approved drugs for the same conditions: Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "AAV2-hRPE65v2" as an intervention, largest first.
Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
NCT03597399 · 87 participants · Start Jan 10, 2019 · Primary completion Jun 30, 2025
Drug: AAV2-hRPE65v2,voretigene neparvovec-rzyl · For: Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Sites: Los Angeles, California; Miami, Florida; Iowa City, Iowa · 10 sites in all
- Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)Active, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT03602820 · 41 participants · Start Jun 2015 · Primary completion Jan 2030
Drug: AAV2-hRPE65v2 · For: Inherited Retinal Dystrophy Due to RPE65 Mutations
- Safety and Efficacy Study in Subjects With Leber Congenital AmaurosisPivotal-lookingActive, not recruiting
Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
NCT00999609 · 31 participants · Start Oct 2012 · Primary completion Jul 2015
Drug: AAV2-hRPE65v2,voretigene neparvovec-rzyl · For: Inherited Retinal Dystrophy Due to RPE65 Mutations; Leber Congenital Amaurosis
Sites: Iowa City, Iowa; Philadelphia, Pennsylvania
Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
NCT00516477 · 12 participants (planned) · Start Sep 2007 · Primary completion Mar 20, 2018
Drug: voretigene neparvovec-rzyl · For: Leber Congenital Amaurosis
Sites: Philadelphia, Pennsylvania
- Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2Active, not recruiting
Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
NCT01208389 · 12 participants (planned) · Start Nov 2010 · Primary completion Oct 2027
Drug: voretigene neparvovec-rzyl · For: Leber Congenital Amaurosis
Sites: Philadelphia, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- Durable Safety and Efficacy of Voretigene Neparvovec-Rzyl in Postapproval Studies in the USA: CRAning for Perfection.
Bennett J · Ophthalmology 2026
- Voretigene Neparvovec (Luxturna) for Biallelic RPE65-Associated Retinal Dystrophy: Systematic Review.
Butt AB, Zaman M, Mihalache A, et al. · Am J Ophthalmol 2026
- Interim Results from a Multicenter Observational Safety Study of Patients Treated with Voretigene Neparvovec-Rzyl in the United States.
Nagiel A, Russell SR, Lam BL, et al. · Ophthalmology 2026
- Clinical Experience with Gene Therapy for Autosomal Recessive RPE65-Related Retinal Dystrophy in the United Arab Emirates.
Khan Z, Ghazi NG, Hay S, et al. · Ophthalmol Retina 2026
- Does Route of Administration Affect the Outcome of Retinal Gene Therapy Clinical Trials?
Marmorstein AD, Beltran WA, Scruggs BA · J Ocul Pharmacol Ther 2026
- Four-Year Structural and Functional Outcomes of the First Subretinal Voretigene Neparvovec-rzyl Treatment for RPE65-Associated Inherited Retinal Dystrophy in South Korea.
Hwang S, Son KY, Kim SJ · Korean J Ophthalmol 2026
Also in development for Leber Congenital Amaurosis
- sepofarsenQR-110Phase 32 trials
Laboratoires Thea · Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis
- ATSN-101Phase 21 trial
Atsena Therapeutics Inc. · Leber Congenital Amaurosis, LCA, LCA1
- OCU400Phase 21 trial
Ocugen · Retinitis Pigmentosa, Leber Congenital Amaurosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.